KHẢO SÁT TÌNH HÌNH SỬ DỤNG THUỐC VÀ HIỆU QUẢ ĐIỀU TRỊ VIÊM LOÉT DẠ DÀY TÁ TRÀNG DO H.PYLORI TẠI BỆNH VIỆN ĐA KHOA ĐỒNG NAI

Abstract

Objectives: This study aims to analyze the use of drugs treating Helicobacter pylori-associated peptic ulcer disease and evaluate the therapeutic outcome of regimen treating H.pylori. Methods: Retrospective, cross-sectional, descriptive of prescriptions and therapeutic outcome to outpatients with H.pylori diagnosis. Results: The most commonly used regimen is PBMT, accounting for 77,8%; the main concomitant drug is antacid 50,9%. The most common ADE was diarrhea (28,6%). The mean time for the treatment regimen was 14 days. Effective treatment: the number of patients who had no clinical symptoms was 78%, the rate of H. Pylori eradication compared to the number of patients who went for re-examination and breath test was 94%. 3 factors: gender (p=0,005, OR=2,968, 95% CI 1,557-15,812), medication adherence (p=0,028, OR=11,971, 95% CI 1,311-109,283) and occupation (p=0,049, OR = 7,005, 95% CI 0,99-49,568) is related to the patient's treatment effect. Conclusion: The drugs used in the treatment of peptic ulcers caused by H. Pylori are mostly consistent with the reference guidelines. Gender, occupation and level of medication adherence are factors related to treatment effectiveness.